By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – http://careers.regeneron.com


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 





Collaborations

Sanofi US 

Bayer 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotech 





Company News
Regeneron (REGN) Jumps Despite Ditching Development Of RSV Med 8/14/2017 7:41:06 AM
Regeneron (REGN) Heading for Another Hiring Ramp 8/8/2017 8:04:01 AM
Accessing the Regeneron (REGN) Second Quarter 2017 Financial And Operating Results Webcast 8/3/2017 12:42:23 PM
Regeneron (REGN) to Terminate Its Antibody Discovery Pact With Sanofi (SNY) 8/3/2017 7:39:31 AM
Earnings Preview: What To Expect From Regeneron (REGN) on Thursday 8/2/2017 6:19:53 AM
Sanofi (SNY) And Regeneron (REGN) Receive Positive CHMP Opinion For Dupixent (Dupilumab) To Treat Adult Patients With Moderate-To-Severe Atopic Dermatitis 7/21/2017 8:43:26 AM
Regeneron (REGN) To Report Second Quarter 2017 Financial And Operating Results And Host Conference Call And Webcast On August 3, 2017 7/13/2017 9:11:48 AM
Regeneron (REGN) And Sanofi (SNY) Announce Approval Of Kevzara (Sarilumab) To Treat Adult Patients With Moderately To Severely Active Rheumatoid Arthritis In The European Union 6/27/2017 7:05:10 AM
Regeneron (REGN) Details Royalty Agreement With Novartis AG (NVS) For Canakinumab (ACZ885) 6/22/2017 7:47:17 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
12345678910...
//-->